The Christ Hospital Structural Heart ...

Dr. Santiago Garcia, MD

Claim this profile

The Christ Hospital

Studies Von Willebrand Disease
Studies Aortic Valve Disease
15 reported clinical trials
20 drugs studied

Affiliated Hospitals

Image of trial facility.
The Christ Hospital
Image of trial facility.
Abbott Northwestern Hospital

Clinical Trials Santiago Garcia, MD is currently running

Image of trial facility.

Transcatheter Valve Repair

for Mitral Regurgitation

This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
Recruiting1 award N/A9 criteria
Image of trial facility.

Proteomics Analysis

for Heart Valve Disease

The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT. The study population will be adult patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration. Enrollment will continue until 30 patients with HALT are identified for completion of phase 1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients. Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0), post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the occurrence of HALT. Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which point a follow-up CT scan and blood sample will be obtained. Control subjects will also undergo a 6-month study visit with blood sample collection. The study will be conducted within two phases. Phase 1 will serve as a derivation / discovery study in which candidate protein biomarkers of HALT will be identified. Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2 will be performed under the auspices a future contract or amendment and will seek to cross-validate the initial study findings.
Recruiting1 award Phase 13 criteria

More about Santiago Garcia, MD

Clinical Trial Related7 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Santiago Garcia, MD has experience with
  • Edwards PASCAL System
  • ACURATE Neo2™ Transfemoral TAVR System
  • Medtronic CoreValve TAVR System
  • Edwards SAPIEN 3 TAVR System
  • ACURATE Prime™ Transfemoral TAVR System XL
  • Sentinel® Cerebral Protection System

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Santiago Garcia, MD specialize in?
Is Santiago Garcia, MD currently recruiting for clinical trials?
Are there any treatments that Santiago Garcia, MD has studied deeply?
What is the best way to schedule an appointment with Santiago Garcia, MD?
What is the office address of Santiago Garcia, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security